Promore Pharma: LL-37 HEAL trial ahead of schedule
All patients have now been recruited to the Phase 2b HEAL LL-37 trial, ahead of previously communicated time plan (early 2020). This is a crucial step for the company, as it enables delivering top-line results in Q4 2020.